References
1. A synthetic inhibitor of the mitogen-activated protein kinase cascade: D.T. Dudley, et al.; PNAS 92, 7686 (1995)|2. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor: L. Pang, et al.; J. Biol. Chem. 270, 13585 (1995) |3. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo: D. Alessi, et al.; J. Biol. Chem. 270, 27489 (1995)|4. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production: F.J. Dumont, et al.; J. Immunol. 160, 2579 (1998)|5. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts: M. Tresini, et al.; Cancer Res. 58, 1 (1998)|6. PD 098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma: C. Simon, et al.; Br. J. Cancer 80, 1412 (1999)|7. Specificity and mechanism of action of some commonly used protein kinase inhibitors. S.P. Davies, et al.; Biochem. J. 351, 95 (2000)|8. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells: K. Kojima, et al.; Cancer Res. 67, 3210 (2007)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
